Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis

医学 联合疗法 骨髓纤维化 鲁索利替尼 疾病 内科学 肿瘤科 临床试验 重症监护医学 药物治疗 选择(遗传算法) 药品 托法替尼 抗体疗法
作者
Shuai Tan,Yuxin Li,Yaofang Cao,Wanling Sun,Wuhan Hui
出处
期刊:Annals of Medicine [Informa]
卷期号:58 (1): 2634532-2634532 被引量:2
标识
DOI:10.1080/07853890.2026.2634532
摘要

BACKGROUND: Myelofibrosis (MF) is a chronic myeloproliferative neoplasm. Although Ruxolitinib, a JAK1/2 inhibitor, remains the cornerstone of MF treatment, it does not reverse disease progression, and resistance frequently emerges. These limitations have prompted investigation into combination therapies targeting pathways beyond the JAK-STAT axis. This meta-analysis aims to evaluate the efficacy and safety of Ruxolitinib-based combination therapies in patients with MF. METHODS: We conducted a systematic search of databases for studies published through August 1, 2025. Thirteen distinct Ruxolitinib-based combination regimens were included. Primary efficacy endpoints were ≥35% spleen volume reduction at 24 weeks (SVR35) and ≥50% reduction in total symptom score (TSS50). Safety endpoints focused on the incidence of grade 3/4 thrombocytopenia and anemia. Subgroup analyses were performed based on prior JAK inhibitor exposure and therapeutic mechanism of action. RESULTS: A total of 19 studies comprising 1,088 patients were included in the meta-analysis. Among JAK inhibitor-naïve patients, the combination of Ruxolitinib with Selinexor demonstrated the highest efficacy (SVR35: 92%; TSS50: 78%), followed by Ruxolitinib plus BMS-986158 (SVR35: 90%). For patients with prior JAK inhibitor exposure, Ruxolitinib plus Siremadlin (SVR35: 45%) showed notable activity. CONCLUSION: For JAK inhibitor-naïve patients, Ruxolitinib-based combination regimens demonstrated satisfactory clinical responses and the potential for meaningful disease control. For patients with prior JAK inhibitor exposure, the addition of combination therapy drugs may further enhance the efficacy. Personalized treatment selection remains essential, as therapeutic efficacy is significantly influenced by prior JAK inhibitor exposure.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
syvshc的应助被科研通管家采纳,获得10
刚刚
刚刚
DW的应助被科研通管家采纳,获得10
刚刚
Orange的应助被科研通管家采纳,获得10
1秒前
鸟窝的应助被科研通管家采纳,获得10
1秒前
笑容完成签到,获得积分10
1秒前
深情安青的应助被科研通管家采纳,获得10
1秒前
我是老大的应助被科研通管家采纳,获得10
1秒前
1秒前
xx发布了新的文献求助30
1秒前
充电宝的应助被科研通管家采纳,获得10
1秒前
秋风的应助被科研通管家采纳,获得10
1秒前
上官若男的应助被下载采纳,获得10
1秒前
1秒前
SciGPT的应助被科研通管家采纳,获得10
1秒前
Akim的应助被科研通管家采纳,获得10
2秒前
领导范儿的应助被科研通管家采纳,获得10
2秒前
桐桐的应助被科研通管家采纳,获得10
2秒前
秋风的应助被科研通管家采纳,获得20
2秒前
动听绿茶发布了新的文献求助10
2秒前
Gallavich发布了新的文献求助30
2秒前
烟花的应助被科研通管家采纳,获得10
2秒前
Owen的应助被科研通管家采纳,获得10
2秒前
2秒前
molihuakai的应助被科研通管家采纳,获得10
2秒前
无花果的应助被科研通管家采纳,获得10
3秒前
传奇3的应助被释然zc采纳,获得10
3秒前
搜集达人的应助被科研通管家采纳,获得10
3秒前
九月初发布了新的文献求助10
3秒前
情怀的应助被科研通管家采纳,获得10
3秒前
winwin发布了新的文献求助10
3秒前
Lucas的应助被科研通管家采纳,获得10
3秒前
bkagyin的应助被cherish采纳,获得10
3秒前
无极微光的应助被科研通管家采纳,获得20
3秒前
忧郁芷烟完成签到,获得积分10
3秒前
3秒前
DW的应助被科研通管家采纳,获得10
3秒前
烟花的应助被顺利采纳,获得200
4秒前
万能图书馆的应助被许可991127采纳,获得10
4秒前
molihuakai的应助被Donghaol采纳,获得10
4秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183046
求助须知:如何正确求助?哪些是违规求助? 9572370
关于积分的说明 21824411
捐赠科研通 7779694
什么是DOI,文献DOI怎么找? 3433792
关于科研通互助平台的介绍 2558024
邀请新用户注册赠送积分活动 2479971